Ozempic Costs Across Federal Programs, Compared

Last updated 2 weeks ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

Ozempic is a type 2 diabetes medicine for adults, made by Novo Nordisk as an injection pen and as a daily pill. Someone shopping for it can find a Medicare price, a Department of Veterans Affairs (VA) copay table and a cash offer that seem to describe the same medicine. They do not describe the same bill. Federal programs cover and pay for Ozempic under different rules; some posted figures are not patient prices at all.

Even when a patient can use more than one route, the cheapest number on a page may not apply to their pen or tablet, dose or pharmacy. The useful comparison is what the same prescription costs under each route the patient can actually use.

Why these prices are not interchangeable

The Food and Drug Administration’s Ozempic tablet label describes a once-daily pill for adults with type 2 diabetes, including a cardiovascular-risk indication. The agency’s injection label describes a different Ozempic product, with type 2 diabetes, cardiovascular and kidney-risk indications. The tablet label covers both Ozempic and Rybelsus tablets and cautions that the two are not interchangeable milligram for milligram. It directs patients to take an oral dose once daily.

A daily pill and an injection are different regimens, so a cost comparison should start with the actual prescription, not with semaglutide, the ingredient the products share. A prescription for one form does not establish that a plan will cover the other. The pill and pen also have different listed strengths; an offer for a pen starting dose cannot be used to price a month of tablets.

Novo Nordisk defines a list price as the manufacturer’s price before discounts or rebates. The manufacturer says the amount a patient pays depends on insurance coverage. A federal purchaser’s price, an insurer’s allowed price, an advertised cash price and a person’s copay answer different questions.

In its fact sheet on the prices Medicare negotiated with drug companies for 2027, the Centers for Medicare & Medicaid Services (CMS) lists Ozempic together with two other Novo Nordisk products, Rybelsus and Wegovy, at $274 for a 30-day supply. A separate CMS example applies the negotiated price to a single package and gives $276.78 for one 4 mg/3 mL Ozempic pen. The figures differ because one is a group-level 30-day figure and the other is a package example; neither is a patient-specific quote.

Part D is Medicare’s prescription drug coverage. A formulary is a plan’s approved list of covered drugs. VA posts its copay rates for 2026, while Federal Employees Health Benefits (FEHB) plans, working under Office of Personnel Management (OPM) guidance, have their own formularies and costs rather than one federal pharmacy price.

Medicare: negotiated price versus the pharmacy bill

Medicare says Part D drug costs depend on the plan selected. Plans may use prior authorization, step therapy and quantity limits. Step therapy means trying a proven, less expensive covered drug first; quantity limits cap how much of a drug the plan covers over a set period. Prior authorization is plan approval that the patient or prescriber must get before certain drugs are covered. The prescriber may need to show that the drug is medically necessary and that the patient meets the plan’s conditions, which can include a particular diagnosis. A beneficiary therefore needs the precise Ozempic product on the plan’s current drug list, not just a statement that Medicare covers prescription drugs.

For 2026, a Part D plan’s deductible cannot exceed $615, although some plans have no deductible. Medicare’s 2026 annual out-of-pocket threshold is $2,100 for covered Part D drugs, counting certain payments made on a beneficiary’s behalf. The deductible and annual limit describe different stages of coverage; neither turns the future $274 negotiated amount into a flat copay.

CMS says its negotiated prices will be effective January 1, 2027. Until then, an estimate must use the existing plan’s 2026 terms. Medicare’s plan comparison lets a person compare estimated monthly and yearly costs. It also advises checking whether the plan covers the prescriptions and includes the pharmacy.

When coverage begins, a plan may offer a one-time 30-day transition fill for a medicine that is not on its list or still needs authorization. That temporary supply does not guarantee continuing coverage; ask the plan what must happen before the next refill.

GLP-1 stands for glucagon-like peptide-1; medicines in this class help keep blood sugar from rising too high after eating or drinking. The Medicare GLP-1 Bridge, a CMS program for certain drugs in Ozempic’s class that runs from July 1, 2026, through Dec. 31, 2027, covers Wegovy, Foundayo and the KwikPen form of Zepbound for weight management, not Ozempic. CMS says a beneficiary with type 2 diabetes is ineligible for the Bridge, whether or not the person’s Part D plan covers a drug in that class for the condition. The Bridge’s $50 copay applies only when a drug is prescribed for weight management, so it cannot be used as an Ozempic quote.

Medicaid: state rules determine the answer

All states provide outpatient prescription coverage to categorically eligible Medicaid enrollees and most other enrollees. Such eligibility is through a mandatory or optional Medicaid group, including groups for families, children, pregnant women, and people who are older, blind or disabled. That broad coverage is not a promise that every Ozempic form or use is covered without conditions. CMS publishes state prescription-drug resources describing each state’s coverage and reimbursement methods. For an actual amount, a beneficiary needs their state’s or managed-care plan’s drug list, authorization rules and pharmacy information.

The Medicaid Drug Rebate Program offsets federal and state program spending. A rebate lowers what the government pays; it does not set a patient’s Ozempic copay.

Federal Medicaid rules allow state cost sharing that varies with income, while exempting some groups and services. Medicaid’s federal cost-sharing rules generally keep charges nominal for low-income enrollees. They exempt children, terminally ill people and residents of institutions from many out-of-pocket charges. A household should not assume a copay quoted by someone in another state or eligibility group applies to its own prescription.

VA and TRICARE: different eligibility and pharmacy routes

A VA Pharmacy Benefits Management decision from April 2026 lists updated Ozempic injection criteria for type 2 diabetes. That document does not establish an Ozempic pill benefit or a single veteran price. VA says its 2026 copay obligation can vary by disability rating, income and eligibility.

For veterans who owe medication copays, VA’s table lists $11 for a 1-to-30-day tier-three brand-name supply, with lower amounts for other tiers and a $700 annual medication-copay cap. The tier assigned to a particular approved prescription has to be checked with VA; the published table alone does not price Ozempic.

TRICARE, the military’s health program, covers Ozempic for type 2 diabetes with approved prior authorization, its pharmacy administrator, Express Scripts, says. The administrator provides a drug lookup for checking formulary status, costs and authorization requirements.

TRICARE’s pharmacy table lists no copay for covered formulary drugs at military pharmacies, with different charges for home delivery and network retail fills for many beneficiaries. The table compares up to 90 days through home delivery with up to 30 days at a retail network pharmacy. The different supply lengths make a raw comparison of the listed copays misleading. A TRICARE member should check the drug category and personal beneficiary group before reading a row of that table as their own price.

Federal employee and Marketplace coverage

OPM negotiates each FEHB plan’s benefits and rates annually. There is no national FEHB Ozempic copay to quote. A federal employee needs their own plan’s current formulary and benefit brochure, then an estimate for the prescribed form and pharmacy.

HealthCare.gov tells Marketplace enrollees to check the insurer’s drug formulary and Summary of Benefits and Coverage. A Marketplace plan’s total cost includes premium, deductible, copays or coinsurance, and an out-of-pocket maximum. A low monthly premium alone cannot tell a shopper whether an Ozempic prescription is affordable over a year.

HealthCare.gov says plans can require an in-network pharmacy. If an insurer denies a request for a coverage exception, a patient may appeal the decision. A first insurance quote can be higher than the plan’s final covered cost if the pharmacy is out of network or a denial is still unresolved.

TrumpRx: the cash offer and its limits

HealthCare.gov describes TrumpRx.gov as a site that connects shoppers to special offers and low prices for certain prescription drugs and works outside Marketplace coverage. The TrumpRx Ozempic pen page advertises $199 for each of two introductory monthly fills at 0.25 or 0.5 milligrams for eligible new self-pay patients through Dec. 31, 2026. It lists $349 per month for later 0.25, 0.5 or 1 milligram fills and $499 for 2 milligrams. The pen page directs an eligible shopper to present its coupon at the pharmacy. A patient already on the medicine, on a different dose, or filling after the offer window cannot assume the starter figure.

Novo Nordisk’s Ozempic price page lists pill self-pay prices of $149, $199 and $299 for 1.5, 4 and 9 milligrams, respectively, per 30-tablet month. The pill offer asks for a valid prescription and a coupon presented at the pharmacy.

Novo Nordisk says Medicare Part D beneficiaries may use a self-pay offer outside their coverage but are not eligible for its “pay as little as $25” offer for patients with commercial insurance. It says Medicaid beneficiaries may also use a self-pay route outside their coverage. The TrumpRx page for the pill offer, however, says “Government beneficiaries excluded.” For the pill, the manufacturer’s statement and the TrumpRx page do not match.

The pen offer’s terms say the self-pay purchase cannot be reimbursed by insurance and cannot count toward the deductible or out-of-pocket limit. Government-program enrollees, including Medicare, Medicaid, VA and TRICARE members, can use this pen self-pay offer if they are at least 18, live in the United States or one of its listed territories, and have a valid prescription; they must also disclose the outside-plan purchase if their insurer asks, without seeking reimbursement. Someone with a government program should check the precise offer’s eligibility before relying on a cash figure; someone with coverage should compare the covered price and the cash price separately.

Get a price that applies to the prescription

HealthCare.gov advises Marketplace enrollees to find the lowest cash price on TrumpRx and compare it with what they pay under their plan. Start with the clinician’s exact product, form, strength, dose and reason for prescribing; a plan may evaluate a different use differently. Then check the relevant plan or program’s live formulary, authorization rules, pharmacy network and estimated cost for that prescription.

A Medicare enrollee can use Medicare’s plan comparison to estimate annual drug cost. A Medicaid enrollee can start with the state prescription-drug resources. A TRICARE beneficiary can check the current TRICARE formulary. A Marketplace enrollee can use the insurer’s drug list and benefits summary. VA patients and federal employees need their own care team or plan, because those systems do not produce a universal Ozempic quote.

Ask the pharmacist to compare the covered claim with any eligible cash offer before filling, and ask which payment will count toward the applicable spending limit. Two dates make a later recheck worthwhile: the pen’s introductory cash offer runs through Dec. 31, 2026, and Medicare’s negotiated price begins in 2027.